WO2001034121A2 - Mehrschichtige filmförmige zubereitung aus hydrophilen polymeren zur schnellen freisetzung von wirkstoffen - Google Patents

Mehrschichtige filmförmige zubereitung aus hydrophilen polymeren zur schnellen freisetzung von wirkstoffen Download PDF

Info

Publication number
WO2001034121A2
WO2001034121A2 PCT/EP2000/010856 EP0010856W WO0134121A2 WO 2001034121 A2 WO2001034121 A2 WO 2001034121A2 EP 0010856 W EP0010856 W EP 0010856W WO 0134121 A2 WO0134121 A2 WO 0134121A2
Authority
WO
WIPO (PCT)
Prior art keywords
layer
preparation according
layers
film
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/010856
Other languages
German (de)
English (en)
French (fr)
Other versions
WO2001034121A3 (de
Inventor
Markus Krumme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00983105A priority Critical patent/EP1227801B1/de
Priority to AU19981/01A priority patent/AU778619B2/en
Priority to DE50013472T priority patent/DE50013472D1/de
Priority to JP2001536121A priority patent/JP4213383B2/ja
Priority to US10/129,835 priority patent/US7332230B1/en
Priority to CA002391406A priority patent/CA2391406C/en
Priority to IL14957300A priority patent/IL149573A0/xx
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of WO2001034121A2 publication Critical patent/WO2001034121A2/de
Publication of WO2001034121A3 publication Critical patent/WO2001034121A3/de
Priority to IL149573A priority patent/IL149573A/en
Anticipated expiration legal-status Critical
Priority to US11/932,345 priority patent/US7803430B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/31504—Composite [nonstructural laminate]
    • Y10T428/31855—Of addition polymer from unsaturated monomers
    • Y10T428/31909—Next to second addition polymer from unsaturated monomers
    • Y10T428/31913—Monoolefin polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/31504—Composite [nonstructural laminate]
    • Y10T428/31855—Of addition polymer from unsaturated monomers
    • Y10T428/31909—Next to second addition polymer from unsaturated monomers
    • Y10T428/31928—Ester, halide or nitrile of addition polymer

Definitions

  • Multi-layer film-like preparation made of hydrophilic polymers for the rapid release of active ingredients
  • the invention relates to a multilayer, film-shaped
  • the invention relates to preparations of the type mentioned, the layers of which contain pharmacologically active substances.
  • the invention further relates to a method for producing such preparations and their use.
  • the material-releasing composition must also be as compact as possible in order to give the system sufficient strength and to enable good handling.
  • the area is not extended without restriction.
  • Such films can be obtained by preparing a solution which contains the polymer matrix in a hydrophilic solvent, usually water. This solution is mixed with active ingredients and auxiliary substances on a process film made of plastic or metal.
  • Drying removes the solvent and the polymer matrix remains as a film.
  • Such relatively thin films offer the advantage that they dissolve relatively quickly in the organism and thus cause a rapid release of active ingredient.
  • the film thickness is limited due to the manufacturing process, this also results in a restriction with regard to the loading with active substances. Therefore, single-layer films have the disadvantage of a low maximum possible total dose. If combination preparations with the properties mentioned are required, the chemical incompatibility of two or more active ingredients, or also other ingredients, for example flavorings, is a further possible problem with these thin films.
  • the object of the present invention was therefore to provide a composition for the delivery of pharmacological or other active substances which, with compact dimensions, enables a high active substance loading and at the same time a rapid release at the application site.
  • a composition should be readily soluble in aqueous media, for example in body fluids.
  • it was required that such a composition also enable the joint administration of active ingredients or other ingredients that are incompatible with one another. Further a little laborious process should be demonstrated by which the composition can be made.
  • the object is achieved in that, in the case of a multilayer film-like preparation of hydrophilic polymers, the adjacent layers differ from one another in that one layer is soluble in a non-aqueous solvent in which the respective adjacent layer is not or only sparingly soluble.
  • Such a structure enables a manufacturing process in which first a film of resin-containing ("base film”) solution, e.g. is prepared in water, the present hydrophilic polymers and then a further solution of film-forming polymers is applied to the existing base film, the latter polymers being dissolved in a non-aqueous solvent in which the base film prepared first is not or only sparingly soluble.
  • base film resin-containing
  • the base film can consist of a polymer or polymer mixture which is water-soluble, while the polymer or polymer mixture is soluble for the subsequent, adjacent film layer in higher alcohols or in chloroform, the polymers of the base layer being insoluble in these organic solvents.
  • the solubility of the polymers of the subsequently applied layer in organic solvents does not preclude them from being readily water-soluble.
  • coating with a second (or with another) active ingredient-containing layer on an already existing layer is made possible without the already existing layer being attacked or dissolved by the solvents used to produce the adjacent film layer.
  • the thickness of the individual layers can be kept small, with the advantage that the drying times during manufacture can be shortened.
  • the multilayer systems according to the invention enable an active ingredient loading which is higher than in single-layer systems, the total loading increasing proportionally with the number of layers present. This higher active ingredient loading is achieved without having to accept an increase in the film surface and a loss of compactness.
  • the multilayer structure also enables active ingredients or other releasable ingredients which are not chemically compatible with one another to be present within the same preparation, but in different layers. In this way, active ingredients, flavorings or other ingredients that are incompatible with one another can be spatially separated from one another and combination preparations can be provided that would otherwise not be possible with a film-like dosage form.
  • the stability of such medicinal forms can also be improved by distributing incompatible ingredients over different film layers.
  • the film-like multilayer preparation according to the invention has a favorable ratio of surface area to volume, the active ingredient can be released quickly into a liquid environment by diffusion.
  • the dissolution time is longer than with single-layer systems, but with a suitable formulation it is still sufficiently short so that it does not represent the rate-determining step in the release of active substance.
  • a rapid dissolution of the preparation may also be desirable for other reasons, for example if the preparation is used to produce pharmaceutical forms which are used in the oral cavity.
  • the achievable release rate is characterized according to one embodiment of the invention, that for the dissolution of a preparation with an area of at most 10 cm 2 in physiological liquids, or artificial replicas of such liquids, a period of at most 15 minutes, preferably at most 5 minutes, especially preferably of at most 1 min.
  • the preparations according to the invention for the administration of pharmacologically It is advantageous for active substances in humans or animals if, owing to their structure, they enable the substances to be released from the film layers by dissolving these layers through physiological fluids or artificial replicas thereof, preferably body fluids from humans or animals. This can be done by selecting suitable water-soluble film-forming polymers and other soluble additives, the suitable polymers or additives being known to the person skilled in the art.
  • the polymer layers of the film-like preparation according to the invention are suitable as a matrix for the absorption and later release of ingredients of various kinds.
  • Substances which are selected from the group which comprises pharmacological active substances, substances with a refreshing effect, flavorings, flavorings and sweeteners are preferably used. These substances can be present individually or in combinations in a certain layer, whereby the compatibility of the substances with one another must be taken into account.
  • the film layers contain the active ingredient (s) or other ingredients in dissolved, emulsified or suspended form.
  • Embodiments of the invention are particularly preferred which contain at least one pharmacological active ingredient in at least one of the film layers. Likewise, one or more layers can also contain combinations of active ingredients.
  • the layer structure can be designed in a wide range.
  • composites are possible in which, starting from a base layer, further layers are applied one after the other in the manner described.
  • a symmetrical structure is also possible, in which a further layer is applied to both sides (top and bottom) of a base layer, and optionally further layers.
  • the composition is composed of two water-soluble layers, one layer being additionally soluble in an organic solvent or a mixture of such solvents in which the other layer is not soluble.
  • Another particularly preferred composition has a structure of three water-soluble film layers.
  • the two outer layers are additionally soluble in an organic solvent or a mixture of such solvents in which the middle layer is not soluble.
  • the middle layer corresponds to the base layer in terms of the order in which it was manufactured.
  • Suitable hydrophilic film-forming polymers for producing the multilayer film-like compositions according to the invention are, in particular, those with high water solubility, especially various cellulose ethers, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, also copolymers of the polymers mentioned, and alginates, gelatin and various other substances known to the expert, which can be synthetic, semi-synthetic or natural.
  • compositions in which the base layer of polyvinyl alcohol or mixtures thereof is constructed for example, from a low viscosity partially hydrolyzed polyvinyl alcohol (Mowiol ® 8-88, Fa. Riant CLA).
  • Polyvinyl alcohols are readily soluble in water, but not, for example, in ethanol. The latter solvent can therefore be used according to the invention to apply a further film layer to this base layer made of polyvinyl alcohol.
  • cellulose ethers preferably hydroxymethylpropyl cellulose, or mixtures of cellulose ethers are used for the production of the base layer.
  • polyvinyl alcohols or cellulose ethers can also be used for the production of the following (adjacent) layers, if the order of manufacture of the multilayer preparations is different.
  • one or more further layers of the multilayer film formulation according to the invention polyvinylpyrrolidone is used as the hydrophilic, water-soluble film forming polymer for the production, for example, Kollidon ® (Fa. BASF).
  • the properties of the preparations according to the invention can be optimized by adding auxiliaries or additives and adapted to the respective requirements. These include, for example, plasticizers, pigments, decay promoters, wetting agents, substances that require absorption or permeation, Structurizer and texture modifier, the selection of suitable additives being known to the person skilled in the art.
  • the multilayer film preparations according to the invention preferably have a thickness of at least 100 ⁇ m, particularly preferably a thickness of at least 150 ⁇ m.
  • the multilayer film-like preparations can be produced in a simple, time-saving and inexpensive manner using the methods proposed according to the invention.
  • a polymer solution is first prepared, which contains the desired active ingredients, optionally together with auxiliary substances.
  • This solution is coated on an inert process film made of plastic or metal, which can be done by doctor blade, roller application or spraying.
  • a primary film, also called a base layer, is then obtained by drying.
  • another polymer solution containing the active ingredient is applied to this base layer using the same methods, a solvent or solvent mixture which does not attack or dissolve the primary layer being used for the preparation of this polymer solution. It is then dried again and a two-layer composite is obtained.
  • One or more further layers can subsequently be applied to this two-layer composite, taking into account the teaching according to the invention with regard to the selection of the solvents.
  • the added third layer can either have the same composition as the second, so that a symmetrical structure results. animals, or another. In any case, however, the polymer or the polymers of this third layer must be present according to the teaching of the invention in a solvent or mixture which does not attack or dissolve the primary layer.
  • the first layer is produced from a polymer melt which contains the desired active ingredients and, if appropriate, auxiliaries or additives.
  • the melt is preferably applied to an inert process film or other inert substrate by doctor blade, roller application, spraying or extrusion processes.
  • a primary film also called a base layer is obtained from this by cooling and / or drying.
  • this primary film with further polymer films containing active ingredients to produce a multilayer preparation is carried out starting from polymer solutions in the manner already described, although in this case it should also be noted when selecting the polymers or solvents that these are the primary layer or, if appropriate, the not attack or dissolve other already existing film layers.
  • Process foils or metal foils or tapes are preferably used as inert substrates for continuous processes, whereas any inert substrates can be used in the case of discontinuous processes.
  • the preparations according to the invention are preferably suitable for dispensing active pharmaceutical ingredients in human or animal body fluids, or else artificial ones Replicas of it.
  • they can be used advantageously to apply pharmacologically active substances or other substances in the mouth, nose or throat or other body openings or body cavities of the human or animal organism, oral administration being particularly preferred.
  • preparations according to the invention results from the fact that they are suitable for the production of medicinal preparations for medicinal therapy or prophylaxis of diseases in humans or animals, preferably medicinal preparations for oral administration.
  • a partially hydrolyzed polyvinyl alcohol of low viscosity ((Mowiol (1?) 8-88, Clariant) is dissolved in hot water.
  • suitable auxiliaries such as plasticizers, pigments, disintegration promoters and similar additives known to the person skilled in the art and the active ingredients a viscous mass forth, the Ge on an inert were subject is coated
  • a well-manageable primary film a which is readily soluble in water
  • the dried primer film has the following composition:.. 28.6 wt .-% Mowiol ® 8 -88, 7.9 wt. -? S titanium dioxide,
  • the dried layer B has the following composition: 32.8% by weight of polyvinylpyrrolidone, 11.5% by weight of hydroxypropyl cellulose, 6.6% by weight of Sfi titanium dioxide, 32.8% by weight of silicon dioxide and 16.4% by weight % Polyethylene glycol.
  • the primary film from Mowiol ® is not chosen for the polymer of the second layer B solvent (ethanol) soluble and hence is inert to said second mass, which can therefore be applied to the primary film.
  • the mixture is dried again and a two-layer solution which is soluble in aqueous solvent systems is obtained
  • this two-layer preparation can optionally be coated with another film on the still free underside of the primary film.
  • the polymer solution used to produce layer B can also be used for this purpose, since this does not dissolve the primary layer.
  • a three-layer composite with the layer sequence BA-B is obtained in this way.
  • This three-layer preparation is also readily soluble in aqueous systems. In total, three times the amount of active ingredient can be administered in such a three-layer system, based on the maximum possible amount of active ingredient, with which a single-layer film preparation can be loaded.
  • film formations with a size of 15 x 15 mm can achieve dissolution times which are 60 s or less by suitable formulations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
PCT/EP2000/010856 1999-11-11 2000-11-03 Mehrschichtige filmförmige zubereitung aus hydrophilen polymeren zur schnellen freisetzung von wirkstoffen Ceased WO2001034121A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU19981/01A AU778619B2 (en) 1999-11-11 2000-11-03 Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients
DE50013472T DE50013472D1 (de) 1999-11-11 2000-11-03 Mehrschichtige filmförmige zubereitung aus hydrophilen polymeren zur schnellen freisetzung von wirkstoffen
JP2001536121A JP4213383B2 (ja) 1999-11-11 2000-11-03 活性成分を急速放出するための親水性ポリマーの薄膜状多層薬剤
US10/129,835 US7332230B1 (en) 1999-11-11 2000-11-03 Multilayer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients
CA002391406A CA2391406C (en) 1999-11-11 2000-11-03 Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients
EP00983105A EP1227801B1 (de) 1999-11-11 2000-11-03 Mehrschichtige filmförmige zubereitung aus hydrophilen polymeren zur schnellen freisetzung von wirkstoffen
IL14957300A IL149573A0 (en) 1999-11-11 2000-11-03 Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients
IL149573A IL149573A (en) 1999-11-11 2002-05-09 Process for the production of a multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients and a use thereof
US11/932,345 US7803430B2 (en) 1999-11-11 2007-10-31 Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19954245A DE19954245A1 (de) 1999-11-11 1999-11-11 Mehrschichtige filmförmige Zubereitung aus hydrophilen Polymeren zur schnellen Freisetzung von Wirkstoffen
DE19954245.7 1999-11-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/932,345 Division US7803430B2 (en) 1999-11-11 2007-10-31 Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients

Publications (2)

Publication Number Publication Date
WO2001034121A2 true WO2001034121A2 (de) 2001-05-17
WO2001034121A3 WO2001034121A3 (de) 2002-04-11

Family

ID=7928670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010856 Ceased WO2001034121A2 (de) 1999-11-11 2000-11-03 Mehrschichtige filmförmige zubereitung aus hydrophilen polymeren zur schnellen freisetzung von wirkstoffen

Country Status (13)

Country Link
US (2) US7332230B1 (https=)
EP (1) EP1227801B1 (https=)
JP (1) JP4213383B2 (https=)
KR (1) KR100731263B1 (https=)
CN (1) CN1407886A (https=)
AR (1) AR026427A1 (https=)
AT (1) ATE339193T1 (https=)
AU (1) AU778619B2 (https=)
CA (1) CA2391406C (https=)
DE (2) DE19954245A1 (https=)
ES (1) ES2272344T3 (https=)
IL (2) IL149573A0 (https=)
WO (1) WO2001034121A2 (https=)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066016A3 (de) * 2001-02-19 2003-10-02 Lohmann Therapie Syst Lts Mucoadhäsive zerfallsfähige arzneizubereitung
WO2004089336A3 (en) * 2003-04-02 2005-03-17 Procter & Gamble Drug delivery systems comprising an encapsulated active ingredient
WO2005115343A2 (de) 2004-05-28 2005-12-08 Abbott Gmbh & Co. Kg Dosierungsform, erhältlich aus einer ein anorganisches pigment umfassenden pulvermischung
WO2006009737A1 (en) * 2004-06-17 2006-01-26 Colgate-Palmolive Company Oral care film
WO2005105038A3 (en) * 2004-04-16 2007-03-29 Hewlett Packard Development Co A system and a method for producing layered oral dosage forms
FR2912915A1 (fr) * 2007-02-28 2008-08-29 Pierre Fabre Medicament Sa Film a desintegration rapide pour l'administration buccale de substances actives.
EP1504765A4 (en) * 2002-05-16 2008-09-03 Kyukyu Yakuhin Kogyo Kk FAST SOLUBLE FILM PREPARATIONS
WO2008130764A1 (en) * 2007-04-18 2008-10-30 Colgate-Palmolive Company Films comprising a plurality of polymers
EP1660056A4 (en) * 2003-08-15 2008-12-17 Arius Two Inc ADHESIVE BIOERODIBLE TRANSMUCOSAL DRUG DELIVERY SYSTEM
KR100912850B1 (ko) * 2001-09-25 2009-08-18 규큐 야쿠힝 고교 가부시키가이샤 니코틴 함유 필름 제제
EP1691631A4 (en) * 2003-11-07 2012-09-05 Us Smokeless Tobacco Co TOBACCO COMPOSITIONS
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US9138124B2 (en) 2010-08-06 2015-09-22 Electrolux Home Products Corporation N.V. Table top dishwasher
US9839939B2 (en) 2013-12-31 2017-12-12 Johnson & Johnson Consumer Inc. Single-pass process for forming a multilayered shaped film product
US9855221B2 (en) 2001-10-12 2018-01-02 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US9931305B2 (en) 2001-10-12 2018-04-03 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US10111810B2 (en) 2002-04-11 2018-10-30 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10661302B2 (en) 2013-12-31 2020-05-26 Johnson & Johnson Consumer Inc. Process for forming a shaped film product
US10821074B2 (en) 2009-08-07 2020-11-03 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US11247226B2 (en) 2013-12-31 2022-02-15 Johnson & Johnson Consumer Inc. Process for forming a multilayered shaped film product
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20307771U1 (de) * 2003-05-19 2004-09-23 Cofresco Frischhalteprodukte Gmbh & Co. Kg Beschichtung und Beutel
US20050079253A1 (en) * 2003-10-10 2005-04-14 Hiroshi Nakamura Bilayer edible sheet
JP5215175B2 (ja) * 2005-05-25 2013-06-19 ユーエス スモークレス タバコ カンパニー リミテッド ライアビリティ カンパニー タバコ組成物
ES2699077T3 (es) 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Apomorfina sublingual
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
PL2415382T3 (pl) 2010-08-06 2013-02-28 Electrolux Home Products Corp Nv Zmywarka nablatowa
PT2651357T (pt) 2010-12-16 2020-06-17 Sunovion Pharmaceuticals Inc Películas sublinguais
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US20140271783A1 (en) * 2011-10-14 2014-09-18 Purdue Research Foundation Prefabricated pharmaceutical dosage forms from functional polymer films
WO2014018075A1 (en) 2012-07-23 2014-01-30 Crayola, Llc Dissolvable films and methods of using the same
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US20170360942A1 (en) * 2014-12-09 2017-12-21 Monosol Rx, Llc Linear polysaccharide based film products
EP4578461A3 (en) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
CN106237338A (zh) * 2016-09-05 2016-12-21 四川大学 一种制备层状生物降解高分子药物控释材料的方法
EP3691610A1 (en) 2017-10-07 2020-08-12 Zim Laboratories Limited Process for the preparation of bi/multi-layer film, multi-layered film produced thereof and apparatus for producing such multi-layer films
DE102017127452A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Wasserlösliche Polymerklebschichten
DE102018101778A1 (de) * 2018-01-26 2019-08-01 Lts Lohmann Therapie-Systeme Ag Mehrschichtiger Oraler Dünnfilm
DE102021100783A1 (de) 2021-01-15 2022-07-21 Lts Lohmann Therapie-Systeme Ag. Mehrschichtiger oraler dünnfilm

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2700035A (en) * 1950-08-26 1955-01-18 Du Pont Production of polyvinyl alcohol
US3511728A (en) * 1964-03-16 1970-05-12 Westinghouse Electric Corp Methods for making flat electrical cables
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
US4439581A (en) * 1981-09-03 1984-03-27 Kanzaki Paper Manufacturing Co., Ltd. Method for the production of microcapsules
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
JPS61280423A (ja) * 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk 口腔内粘膜貼付剤
JPS63171565A (ja) * 1987-01-07 1988-07-15 積水化学工業株式会社 口腔粘膜貼付用構成体およびその製造方法
WO1995005416A2 (en) * 1993-08-19 1995-02-23 Cygnus Therapeutic Systems Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
JPH07196992A (ja) * 1993-12-28 1995-08-01 Nippon Autom Kk 制振シート
JP2791317B2 (ja) * 1995-12-26 1998-08-27 株式会社三和化学研究所 多層フィルム製剤
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US5760484A (en) * 1997-02-11 1998-06-02 Mosel Vitelic Inc. Alignment mark pattern for semiconductor process

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066016A3 (de) * 2001-02-19 2003-10-02 Lohmann Therapie Syst Lts Mucoadhäsive zerfallsfähige arzneizubereitung
US8906406B2 (en) 2001-02-19 2014-12-09 Lts Lohmann Therapie-Systeme Ag Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine
KR100912850B1 (ko) * 2001-09-25 2009-08-18 규큐 야쿠힝 고교 가부시키가이샤 니코틴 함유 필름 제제
US10888499B2 (en) 2001-10-12 2021-01-12 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US9931305B2 (en) 2001-10-12 2018-04-03 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US9855221B2 (en) 2001-10-12 2018-01-02 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10111810B2 (en) 2002-04-11 2018-10-30 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
EP1504765A4 (en) * 2002-05-16 2008-09-03 Kyukyu Yakuhin Kogyo Kk FAST SOLUBLE FILM PREPARATIONS
WO2004089336A3 (en) * 2003-04-02 2005-03-17 Procter & Gamble Drug delivery systems comprising an encapsulated active ingredient
EP1660056A4 (en) * 2003-08-15 2008-12-17 Arius Two Inc ADHESIVE BIOERODIBLE TRANSMUCOSAL DRUG DELIVERY SYSTEM
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
EP1691631A4 (en) * 2003-11-07 2012-09-05 Us Smokeless Tobacco Co TOBACCO COMPOSITIONS
US8469036B2 (en) 2003-11-07 2013-06-25 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US10765140B2 (en) 2003-11-07 2020-09-08 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US10098376B2 (en) 2003-11-07 2018-10-16 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US10945454B2 (en) 2003-11-07 2021-03-16 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US7727576B2 (en) 2004-04-16 2010-06-01 Hewlett-Packard Development Company, L.P. System and a method for producing layered oral dosage forms
WO2005105038A3 (en) * 2004-04-16 2007-03-29 Hewlett Packard Development Co A system and a method for producing layered oral dosage forms
WO2005115343A3 (de) * 2004-05-28 2006-08-17 Abbott Gmbh & Co Kg Dosierungsform, erhältlich aus einer ein anorganisches pigment umfassenden pulvermischung
WO2005115343A2 (de) 2004-05-28 2005-12-08 Abbott Gmbh & Co. Kg Dosierungsform, erhältlich aus einer ein anorganisches pigment umfassenden pulvermischung
AU2005264999B2 (en) * 2004-06-17 2011-04-28 Colgate-Palmolive Company Oral care film
WO2006009737A1 (en) * 2004-06-17 2006-01-26 Colgate-Palmolive Company Oral care film
FR2912915A1 (fr) * 2007-02-28 2008-08-29 Pierre Fabre Medicament Sa Film a desintegration rapide pour l'administration buccale de substances actives.
WO2008107301A3 (fr) * 2007-02-28 2009-04-23 Pf Medicament Film monocouche a desintegration rapide pour l'administration buccale de substances actives
WO2008130764A1 (en) * 2007-04-18 2008-10-30 Colgate-Palmolive Company Films comprising a plurality of polymers
US10821074B2 (en) 2009-08-07 2020-11-03 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US9138124B2 (en) 2010-08-06 2015-09-22 Electrolux Home Products Corporation N.V. Table top dishwasher
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10940626B2 (en) 2010-10-22 2021-03-09 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US11203037B2 (en) 2013-12-31 2021-12-21 Johnson & Johnson Consumer Inc. Apparatus for forming a shaped film product
US10016784B2 (en) 2013-12-31 2018-07-10 Johnson & Johnson Consumer Inc. Apparatus for forming a multilayered shaped film product
US10661302B2 (en) 2013-12-31 2020-05-26 Johnson & Johnson Consumer Inc. Process for forming a shaped film product
US9839939B2 (en) 2013-12-31 2017-12-12 Johnson & Johnson Consumer Inc. Single-pass process for forming a multilayered shaped film product
US11247226B2 (en) 2013-12-31 2022-02-15 Johnson & Johnson Consumer Inc. Process for forming a multilayered shaped film product
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12023309B2 (en) 2016-05-05 2024-07-02 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Also Published As

Publication number Publication date
ATE339193T1 (de) 2006-10-15
EP1227801A2 (de) 2002-08-07
KR100731263B1 (ko) 2007-06-21
ES2272344T3 (es) 2007-05-01
AU1998101A (en) 2001-06-06
JP2003513906A (ja) 2003-04-15
US20080057087A1 (en) 2008-03-06
DE50013472D1 (de) 2006-10-26
CN1407886A (zh) 2003-04-02
US7332230B1 (en) 2008-02-19
IL149573A (en) 2007-09-20
US7803430B2 (en) 2010-09-28
AR026427A1 (es) 2003-02-12
IL149573A0 (en) 2002-11-10
CA2391406A1 (en) 2001-05-17
WO2001034121A3 (de) 2002-04-11
KR20020058006A (ko) 2002-07-12
JP4213383B2 (ja) 2009-01-21
EP1227801B1 (de) 2006-09-13
AU778619B2 (en) 2004-12-16
DE19954245A1 (de) 2001-07-19
CA2391406C (en) 2008-07-29

Similar Documents

Publication Publication Date Title
EP1227801B1 (de) Mehrschichtige filmförmige zubereitung aus hydrophilen polymeren zur schnellen freisetzung von wirkstoffen
EP1227802B1 (de) Filmförmige zubereitung zur biphasigen freisetzung pharmakologisch wirksamer oder anderer substanzen
EP0731692B1 (de) Vorrichtung zur kontrollierten freisetzung von wirkstoffen
DE69921941T2 (de) Verfahren zur Herstellung von pharmazeutischen Wirkstoffpartikeln
AT402689B (de) Dosierungsform für die behandlung kardiovaskulärererkrankungen
DE2525061C2 (de) Formkörper zur Abgabe eines Wirkstoffs und Verfahren zu dessen Herstellung
DE69813225T2 (de) Blockcopolymere
DE69622980T2 (de) Bioadhäsives Arzneimittel zur kontrollierten Freisetzung von Wirkstoffen
DE69817010T2 (de) Spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneiformen
DE2814709A1 (de) Durch osmose wirkende abgabevorrichtung
DE60212475T2 (de) Pharmazeutische Tablette und ein Verfahren zu ihrer Herstellung
DE1617724A1 (de) Verfahren zur Herstellung von Arzneimitteln mit verzoegerter Wirkung
WO1997032570A1 (de) Implantate mit phasenweiser arzneistoffabgabe
DE3943242A1 (de) Vollstaendiger oder partieller ueberzug von pharmazeutischen wirkstoffen und entsprechende zusammensetzungen
DD209574A5 (de) Verfahren zur herstellung einer pharmazeutischen zubereitung in form eines polyacrylatfilms
EP0894495A1 (de) Bioadhäsive Tablette mit Vertiefungen
EP1560564A1 (de) Mehrschichtiges transmucosales therapeutisches system
CH675208A5 (https=)
DE69200474T2 (de) Verfahren zur herstellung einer festem pharmazeutischen zusammensetzung.
DE69001682T2 (de) Wasserdisperierbare gemfibrozilhaltige mittel.
DE60020871T2 (de) Formulierungen mit verlängerter freisetzung zur implantation
EP1383485B1 (de) Magensaftresistente vorrichtung zur freisetzung von mukoadhäsiven wirkstoffträgern und verfahren zur herstellung der magensaftresistenten vorrichtung
DE1467919C (de) Verwendung des Aluminiumsalzes der O-Acetylsalicylsäure in festen Arzneizubereitungsformen mit Depot-Wirkung
WO2000025759A1 (de) Oral applizierbare, mit flüssigkeit spontan zerfallende therapeutische darreichungsform und verfahren zu ihrer herstellung
WO2022152876A1 (de) Orale dünnfilme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ HU IL IN JP KR MX NZ PL RU TR US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ HU IL IN JP KR MX NZ PL RU TR US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 149573

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000983105

Country of ref document: EP

Ref document number: 1020027006077

Country of ref document: KR

Ref document number: IN/PCT/2002/00487/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2001 536121

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2391406

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 19981/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 008167346

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10129835

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020027006077

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000983105

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 19981/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000983105

Country of ref document: EP